YOUNG, E., D. NOERENBERG, L. MANSOURI, V. LJUNGSTROM, M. FRICK, L. A. SUTTON, S. J. BLAKEMORE, J. GALAN-SOUSA,
Karla PLEVOVÁ, P. BALIAKAS, D. ROSSI, R. CLIFFORD, D. ROOS-WEIL,
Veronika NAVRKALOVÁ, B. DOERKEN, C. A. SCHMITT, K. E. SMEDBY, G. JULIUSSON, B. GIACOPELLI, J. S. BLACHLY, C. BELESSI, P. PANAGIOTIDIS, N. CHIORAZZI, F. DAVI, A. W. LANGERAK, D. OSCIER, A. SCHUH, G. GAIDANO, P. GHIA, W. XU, L. FAN, O. A. BERNARD, F. NGUYEN-KHAC, L. RASSENTI, J. LI, T. J. KIPPS, K. STAMATOPOULOS,
Šárka POSPÍŠILOVÁ, T. ZENZ, C. C. OAKES, J. C. STREFFORD, R. ROSENQUIST and F. DAMM. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.
Leukemia. London: Nature Publishing Group, 2017, vol. 31, No 7, p. 1547-1554. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/leu.2016.359.